Pharmion European Thalidomide Application For Multiple Myeloma Withdrawn; Resubmission Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from two ongoing trials are expected to fill out the resubmission. The withdrawal decision was not based on safety issues, Pharmion says.
You may also be interested in...
Pharmion’s Vidaza Approved For IV Administration
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.
Pharmion’s Vidaza Approved For IV Administration
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.
Pharmion Vidaza To Be Launched By July 1 For Bone Marrow Disorder
Approval comes more than a month before FDA’s June 29 action date for azacitidine.